PD
CTNM

Point72 (DIFC)’s Contineum Therapeutics CTNM Stock Holding History

Point72 (DIFC)’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-65
Closed -$258 – 1985
2025
Q2 		$258 Buy
+65
New +$282 ﹤0.01% 1478

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Point72 (DIFC)'s CTNM Position: Q3 2025 in Review

Point72 (DIFC) sold out of Contineum Therapeutics (CTNM) in Q3 2025, closing a stake of 65 shares — an estimated $258 sold.

Point72 (DIFC) first reported a position in CTNM in Q2 2025 and held it in 1 quarter. The position peaked at $258 in Q2 2025. 62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Point72 (DIFC) reported no remaining Contineum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 65 Contineum Therapeutics shares in Q3 2025, an estimated $258.
  • Point72 (DIFC) first reported a position in Contineum Therapeutics in Q2 2025 and held it in 1 quarter.
  • Point72 (DIFC)'s Contineum Therapeutics position peaked at $258 in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.